Current ODB Coverage Status for Ozempic As of January 2024, Ozempic is listed as a Limited Use (LU) benefit under the Ontario Drug Benefit program
Less frequent AEs like hypoglycemia, is mostly seen in combination with insulin or sulfonylureas (157) and some reports of pancreatobiliary complications are partially explained by direct altered absorption of bile acids, rapid weight loss or changes in the gallbladder motility with increased risk of pancreatitis, even though it is extremely rare (160)
For best results, it should be used alongside lifestyle changes such as healthy diet and exercise
Some patients may experience insomnia (trouble sleeping) if they take it too late in the day, so taking it in the morning is often recommended
Clinical trials like SURMOUNT-1 confirm its potential as a powerful anti-obesity agent
Jasonbex 24 July 2026 For those seeking affordable treatments, we recommend visiting national health ministry database